• LAST PRICE
    1.3200
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (2.3256%)
  • Bid / Lots
    1.3200/ 2
  • Ask / Lots
    1.3300/ 1
  • Open / Previous Close
    1.2900 / 1.2900
  • Day Range
    Low 1.2315
    High 1.3200
  • 52 Week Range
    Low 0.8170
    High 2.3300
  • Volume
    31,021
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.29
TimeVolumeMBRX
09:32 ET13861.29
09:33 ET5001.32
09:37 ET21671.2674
09:39 ET1081.2868
09:48 ET1001.25
09:50 ET2921.28
10:18 ET3001.3
10:22 ET7001.3
10:36 ET53501.2315
10:40 ET18001.3099
10:51 ET2001.31
10:56 ET19411.3068
11:02 ET15001.3
11:09 ET1001.3
11:32 ET20001.2702
11:56 ET1001.31
12:01 ET3501.2619
01:00 ET2001.31
01:08 ET1701.294
01:33 ET16001.3025
01:42 ET10821.31
02:12 ET2011.2921
02:16 ET4001.2948
03:08 ET10001.3
03:14 ET3001.29
03:26 ET7271.29
03:30 ET14741.3199
03:37 ET5001.305
03:44 ET8001.31
03:48 ET3001.3
03:55 ET11001.32
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMBRX
Moleculin Biotech Inc
36.9M
-1.5x
---
United StatesONPH
Oncology Pharma Inc
31.3M
0.0x
---
United StatesPCSA
Processa Pharmaceuticals Inc
30.8M
-1.7x
---
United StatesODTC
Odonate Therapeutics Inc
45.5M
-0.6x
---
United StatesEDXC
Endexx Corp
30.8M
-1.5x
---
United StatesIMAB
I-Mab
299.2M
-0.9x
---
As of 2022-11-28

Company Information

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The Company's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.

Contact Information

Headquarters
5300 Memorial Dr Ste 950HOUSTON, TX, United States 77007-8274
Phone
713-300-5160
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Walter Klemp
Chief Financial Officer, Executive Vice President
Jonathan Foster
Chief Scientific Officer
Donald Picker
Senior Chief Medical Officer
Paul Waymack
Independent Director
Michael Cannon

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$36.9M
Revenue (TTM)
$0.00
Shares Outstanding
28.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.85
EPS
$-0.88
Book Value
$2.76
P/E Ratio
-1.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.